DeepMed Research

AGENDIA

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2003-01-01

Employees: -

Market Cap: -

Website: http://www.agendia.com

Clinical Trials

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

Conditions: Breast Cancer

Interventions: Diagnostic Test: MammaPrint, BluePrint, and Full-Genome Testing

First Posted Date: 2017-02-15

Last Posted Date: 2024-06-27

Lead Sponsor: Agendia

Target Recruit Count: 30000

Registration Number: NCT03053193

Locations: 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States

and more 129 locations

Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

Completed

Conditions: Breast Cancer

First Posted Date: 2016-02-02

Last Posted Date: 2018-06-27

Lead Sponsor: Agendia

Target Recruit Count: 481

Registration Number: NCT02670577

Locations: 🇺🇸
Methodist Hospital, Merrillville, Indiana, United States
🇺🇸
Akron General Medical Center, Akron, Ohio, United States
🇺🇸
St. Clair Hospital, Pittsburgh, Pennsylvania, United States

and more 14 locations

The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients

Completed

Conditions: Chinese

First Posted Date: 2016-02-01

Last Posted Date: 2019-07-02

Lead Sponsor: Agendia

Target Recruit Count: 64

Registration Number: NCT02669745

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Completed

Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions: Device: MammaPrint

First Posted Date: 2012-06-13

Last Posted Date: 2016-01-29

Lead Sponsor: Agendia

Target Recruit Count: 820

Registration Number: NCT01617954

Locations: 🇺🇸
Knoxville Comprehensive Breast Center, Knoxville, Tennessee, United States
🇺🇸
Texas Health, Dallas, Texas, United States
🇺🇸
St. Clair Hospital, Pittsburgh, Pennsylvania, United States

and more 50 locations

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: TAC chemotherapy
Drug: TCH chemotherapy
Drug: TC chemotherapy
Drug: T + trastuzumab followed by CEF + trastuzumab
Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
Drug: Dose dense AC followed by T + trastuzumab
Drug: Dose dense AC followed by T + trastuzumab + pertuzumab
Drug: PTH followed by dose dense AC of FEC

First Posted Date: 2011-12-29

Last Posted Date: 2018-06-28

Lead Sponsor: Agendia

Target Recruit Count: 226

Registration Number: NCT01501487

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States

and more 6 locations

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Completed

Conditions: Breast Cancer

Interventions: Other: MammaPrint 70-gene expression profile
Other: BluePrint 80 gene expression profile

First Posted Date: 2011-11-24

Last Posted Date: 2021-01-19

Lead Sponsor: Agendia

Target Recruit Count: 1142

Registration Number: NCT01479101

Locations: 🇺🇸
Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
Fresno Breast Surgery, Fresno, California, United States
🇺🇸
Stamford Hospital, Stamford, Connecticut, United States

and more 72 locations

Validation of 70-gene MammaPrint Profile in Japanese Population

Completed

Conditions: Breast Cancer

First Posted Date: 2009-05-19

Last Posted Date: 2015-06-23

Lead Sponsor: Agendia

Target Recruit Count: 102

Registration Number: NCT00904566

Locations: 🇯🇵
Osaka Medical Center for Cancer and Cadiovascular Diseases, Osaka, Japan

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Conditions: Colon Cancer

First Posted Date: 2009-05-18

Last Posted Date: 2019-01-09

Lead Sponsor: Agendia

Target Recruit Count: 1200

Registration Number: NCT00903565

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 32 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy